Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
2001-05-21
2003-05-20
Rose, Shep K. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
C424S049000, C424S900000, C424S900000
Reexamination Certificate
active
06566350
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition which comprises minocycline or a physiologically acceptable salt thereof as an active ingredient, and which is useful in the treatment or prevention of a periodontal disease such as periodontitis.
BACKGROUND ART
Periodontitis (proximate periodontitis) is a chronic non-specific inflammation occurring not only in gingiva but also in other periodontia, which in most cases develops from periodontitis simplex. In this disease, periodontal pocket, tooth loosening, alveolar bone absorption, and drainage from the pocket are observed, and most of them progress indolently. It is known that certain gram negative bacilli within the periodontal sulcus are involved in periodontitis. For example,
Bacteriodes gingivalis
is involved in adult periodontitis,
Actinobacillus actinomycetemcomitans
is involved in juvenile periodontitis, and
Bacteriodes intermedius
is involved in acute necrotizing ulcerative periodontitis (The Journal of the Japanese Society of Periodontology, Vol. 29 No. 2 pp463-471).
It is known that minocycline is effective in the treatment of periodontal diseases. Minocycline is one type of tetracycline antibiotics which exhibits strong antibiotic action against the aforementioned periodontal pathogenic bacteria, and exhibits superior clinical efficacy against periodontitis (The Journal of the Japanese Society of Periodontology, Vol. 29 No. 2 pp472-483). For example, there is proposed a method of directly applying an ointment comprising minocycline hydrochloride (3.0%), hydroxymethylcellulose and glycerine to the periodontal pocket. Further, “Periocline dental ointment” (sold by Sunstar Inc.) is being used clinically as a periodontitis therapeutic agent.
However, since minocycline is an unstable substance, techniques for providing a stable composition comprising minocycline as an active ingredient, have been examined. For example, in Japanese Patent Publication No. 1-12728, there is disclosed a non-aqueous composition for topical administration characterized in that minocycline or a physiologically acceptable salt thereof is formulated in a base of polyhydric alcohol which comprises a magnesium compound. Further, in Japanese Patent Publication No. 2-34325, there is disclosed a composition for treatment of periodontal diseases wherein minocycline or a physiologically acceptable salt thereof is formulated with a magnesium compound, an aqueous polymeric substance, a polyhydric alcohol, an ethyl methacrylate/ethyl methacrylate-trimethyl ammonium chloride copolymer, and a solubilizer. Furthermore, Japanese Patent Application Laid-Open No. 11-286448 discloses a pharmaceutical composition for topical administration comprising minocycline or a physiologically acceptable salt thereof and an aluminium compound in a polyhydric alcohol base.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a stable pharmaceutical composition for topical administration comprising minocycline as an active ingredient. Another object of the present invention is to provide a substance for stabilizing minocycline formulated in a pharmaceutical composition for topical administration.
As a result of focused and deliberate efforts to achieve the above objects, the present inventors have found that, it was possible to achieve stabilization of minocycline in the oleaginous base, even without the use of stabilizers such as magnesium compounds or aluminium compounds, but with the use of an oleaginous base such as a gelated hydrocarbon in place of the conventionally used polyhydric alcohol. The present invention was completed based on these findings.
Thus, according to the present invention, there is provided a pharmaceutical composition for topical administration comprising minocycline or a physiologically acceptable salt thereof in an oleaginous base.
Preferably, the oleaginous base is a gelated hydrocarbon. More preferably, the gelated hydrocarbon is plastibase.
The pharmaceutical composition according to the present invention preferably further comprises one or more adhesive agent selected from the group consisting of cellulose, cellulose derivatives, water-soluble high molecular compounds and water-soluble starch.
The pharmaceutical composition according to the present invention preferably further comprises a disintegrant.
According to a preferred embodiment of the present invention, there is provided a pharmaceutical composition comprising:
(a) 0.01-15% by weight of minocycline or a physiologically acceptable salt thereof;
(b) 20-97% by weight of an oleaginous base;
(c) 1-60% by weight of an adhesive agent; and
(d) 1-20% by weight of a disintegrant
According to a more preferred embodiment of the present invention, there is provided a pharmaceutical composition comprising:
(a) 0.01-15% by weight of minocycline hydrochloride;
(b) 20-97% by weight of a gelated hydrocarbon;
(c) 1-60% by weight of hydroxypropylmethylcellulose, alpha-converted starch, carboxyvinyl polymer or methylcellulose; and,
(d) 1-20% by weight of a sucrose fatty acid ester.
The pharmaceutical composition of the present invention is preferably used in dental treatment and/or prevention, more preferably in treatment and/or prevention of periodontal diseases.
According to another aspect of the present invention, there is provided an oleaginous base which is used as a stabilizer of minocycline or a physiologically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
The pharmaceutical composition of the present invention is characterized in that it comprises minocycline or a physiologically acceptable salt thereof in an oleaginous base. The pharmaceutical composition of the present invention can be generally prepared as a pharmaceutical composition for topical administration to the oral cavity or periodontia, and preferably as a pharmaceutical composition for dental use. The pharmaceutical composition according to the present invention is preferably provided such that it is suitable for topical administration to the oral cavity or periodontia, for example as a composition in a viscous liquid or paste form. The pharmaceutical composition according to the present invention is useful in the treatment and/or prevention of oral cavity disease or disease in the dental area, for example, periodontal diseases such as periodontitis, periodontal disease, alveolar pyorrhea and the like. Moreover, the use of the pharmaceutical composition according to the present invention is not limited to the above embodiments and is able to be used as an external pharmaceutical composition on the skin or mucosa.
The type of a physiologically acceptable salt of minocycline is not particularly limited. For example, mineral acid salts such as chloride, sulfate or acetate or organic acid salts such as methanesulfonate can be used. Minocycline or a physiologically acceptable salt thereof may be a hydrate or solvate. A solvent which forms the solvate is not particularly limited so long as it is physiologically acceptable, and for example, solvates of ethanol and the like may be used. It is preferred that hydrochloride is used as a salt of minocycline. The content of minocycline or a physiologically acceptable salt thereof contained in the pharmaceutical composition of the present invention is generally about 0.01-15% by weight, preferably about 0.1-5% by weight (as the converted amount to free minocycline) relative to the weight of the composition.
The type of oleaginous base used in the pharmaceutical composition of the present invention is not particularly limited if it is one that is generally used in the pharmaceutical field. For example, gelated hydrocarbon, Vaseline, squalane, isostearic acid, yellow beeswax, liquid paraffin, mid-chain fatty acid triglyceride, cottonseed oil and the like can be used alone or in combination of two or more of them. Preferably, a gelated hydrocarbon may be used. Plastibase (Bristol Myers Squibb), Poloid (Maruishi Pharmaceutical) or the like can be used as the gelated hydrocarbon.
The content of the oleaginous base
Hayakawa Ikuto
Ono Kazuhiro
Sakaguchi Hidenari
Greenblum & Bernstein P.L.C.
Rose Shep K.
Showa Yakuhin Kako Co. Ltd.
LandOfFree
Minocycline-containing compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Minocycline-containing compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Minocycline-containing compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3047208